Bispecific hiv-1 neutralizing antibodies
AssigneeThe Aaron Diamond Aids Research Center
InventorsDavid D. Ho, Yaoxing Huang, Jian Yu
Life of this patent
Estimating the term…
Abstract
In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.
Claims7
1-20. (canceled)
A method of treating HIV infection in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a bispecific antibody in a CrossMab format capable of neutralizing HIV, wherein the antibody comprises a light chain and heavy chain portion of a first antibody 10E8, or a variant thereof, that binds to a HIV envelope protein, and a light chain and heavy chain portion of a second antibody ibalizumab, or a variant thereof, that binds to a cell membrane receptor protein or a cell membrane co-receptor protein,
- wherein the light chain portion of the first antibody 10E8 comprises an amino acid sequence having at least 97% identity with SEQ ID NO:
- 33, and the heavy chain portion of the first antibody 10E8 comprises an amino acid sequence having at least 97% identity with SEQ ID NO:
- 34;
- and the light chain portion of the second antibody ibalizumab comprises an amino acid sequence having at least 97% identity with SEQ ID NO:
- 1, and the heavy chain portion of the second antibody ibalizumab comprises an amino acid sequence having at least 97% identity with SEQ ID NO:
- 2;
- and
- wherein any amino acid alterations relative to SEQ ID NOS:
- 1, 2, 33, and 34 are outside of the variable regions.
A method of treating HIV infection in a patient in need thereof, comprising administering to the patient a bispecific antibody in a CrossMab format capable of neutralizing HIV, wherein the antibody comprises a light chain and heavy chain portion of a first antibody 10E8, or a variant thereof, that binds to a HIV envelope protein, and a light chain and heavy chain portion of a second antibody Pro 140, or a variant thereof, that binds to a cell membrane receptor protein or a cell membrane co-receptor protein,
- wherein the light chain portion of the first antibody 10E8 comprises an amino acid sequence having at least 94% identity with SEQ ID NO:
- 31, and the heavy chain portion of the first antibody 10E8 comprises an amino acid sequence having at least 98% identity with SEQ ID NO:
- 32;
- and the light chain portion of the second antibody Pro 140 comprises an amino acid sequence having at least 97% identity with SEQ ID NO:
- 11, and the heavy chain portion of the second antibody Pro 140 comprises an amino acid sequence having at least 97% identity with SEQ ID NO:
- 12;
- and
- wherein any amino acid alterations relative to SEQ ID NOS:
- 11, 12, 31, and 32 are outside of the variable regions.
Dependencies are inferred from the claim text.